Department of Gastrointestinal Surgery, Guizhou Provincial People's Hospital, Guiyang, 550002, Guizhou Province, China.
Dig Dis Sci. 2013 Jun;58(6):1581-9. doi: 10.1007/s10620-012-2552-2. Epub 2013 Jan 12.
The first identified lysine-specific demethylase, LSD1, plays an important role in the metastatic progression of several types of cancer.
The aim of this study was to investigate LSD1, E-cadherin, and N-cadherin expression in colon cancer specimens and their clinical significance.
The expression of LSD1, E-cadherin, and N-cadherin in colon cancer specimens was determined by immunohistochemistry, and the relationship between the expression of the respective molecules and clinicopathological characteristics was analyzed.
The positive expression rates of LSD1, E-cadherin, and N-cadherin in colon cancer specimens were 66.7 % (72/108), 85.2 % (92/108), and 41.7 % (45/108), respectively. LSD1 was significantly more highly expressed in colon cancer specimens classified as high TNM stage lesions and with distant metastasis (P < 0.05). Further analysis demonstrated that LSD1 expression was positively correlated with lymph node and distant metastases (P < 0.05). However, E-cadherin expression was significantly downregulated in colon cancer specimens classified as high TNM stage lesions and with distant metastasis (P < 0.05), whereas the expression of N-cadherin did not differ significantly according to clinical and pathological characteristics (P > 0.05). Correlation analysis revealed that LSD1 expression was negatively correlated with E-cadherin expression (r s = -0.318, P = 0.001), but not evidently correlated with N-cadherin expression (r s = 0.182, P = 0.06). Colon cancer specimens with positive LSD1 expression and negative E-cadherin expression were correlated with significantly lower overall survival.
LSD1 showed a significantly higher expression, in contrast to the significantly lower expression of E-cadherin, in colon cancer specimens classified as high TNM stage lesions and with distant metastasis. Positive expression of LSD1 and negative expression of E-cadherin may be predictors of a worse colon cancer prognosis.
第一个被鉴定的赖氨酸特异性去甲基酶 LSD1 在多种癌症的转移进展中发挥着重要作用。
本研究旨在探讨 LSD1、E-钙黏蛋白和 N-钙黏蛋白在结肠癌标本中的表达及其临床意义。
采用免疫组织化学法检测 LSD1、E-钙黏蛋白和 N-钙黏蛋白在结肠癌标本中的表达，并分析各分子表达与临床病理特征的关系。
LSD1、E-钙黏蛋白和 N-钙黏蛋白在结肠癌标本中的阳性表达率分别为 66.7%（72/108）、85.2%（92/108）和 41.7%（45/108）。LSD1 在高 TNM 分期病变和远处转移的结肠癌标本中表达明显更高（P<0.05）。进一步分析表明，LSD1 表达与淋巴结和远处转移呈正相关（P<0.05）。然而，E-钙黏蛋白在高 TNM 分期病变和远处转移的结肠癌标本中表达明显下调（P<0.05），而 N-钙黏蛋白的表达与临床病理特征无显著差异（P>0.05）。相关性分析表明，LSD1 表达与 E-钙黏蛋白表达呈负相关（r s=-0.318，P=0.001），但与 N-钙黏蛋白表达无明显相关性（r s=0.182，P=0.06）。LSD1 阳性表达和 E-钙黏蛋白阴性表达的结肠癌标本总生存率明显降低。
LSD1 在高 TNM 分期病变和远处转移的结肠癌标本中表达明显升高，而 E-钙黏蛋白表达明显降低。LSD1 阳性表达和 E-钙黏蛋白阴性表达可能是结肠癌预后不良的预测因子。
